JP2020124212A5 - - Google Patents

Download PDF

Info

Publication number
JP2020124212A5
JP2020124212A5 JP2020076805A JP2020076805A JP2020124212A5 JP 2020124212 A5 JP2020124212 A5 JP 2020124212A5 JP 2020076805 A JP2020076805 A JP 2020076805A JP 2020076805 A JP2020076805 A JP 2020076805A JP 2020124212 A5 JP2020124212 A5 JP 2020124212A5
Authority
JP
Japan
Prior art keywords
hematopoietic cells
specific amount
enlarged
nucleic acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020076805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020124212A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020124212A publication Critical patent/JP2020124212A/ja
Publication of JP2020124212A5 publication Critical patent/JP2020124212A5/ja
Priority to JP2022085669A priority Critical patent/JP2022113722A/ja
Withdrawn legal-status Critical Current

Links

JP2020076805A 2014-03-26 2020-04-23 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法 Withdrawn JP2020124212A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022085669A JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461970787P 2014-03-26 2014-03-26
US61/970,787 2014-03-26

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016559216A Division JP2017511132A (ja) 2014-03-26 2015-03-25 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022085669A Division JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2020124212A JP2020124212A (ja) 2020-08-20
JP2020124212A5 true JP2020124212A5 (https=) 2020-10-01

Family

ID=54196365

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016559216A Pending JP2017511132A (ja) 2014-03-26 2015-03-25 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
JP2020076805A Withdrawn JP2020124212A (ja) 2014-03-26 2020-04-23 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法
JP2022085669A Pending JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016559216A Pending JP2017511132A (ja) 2014-03-26 2015-03-25 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022085669A Pending JP2022113722A (ja) 2014-03-26 2022-05-26 ヒト造血幹／前駆細胞のエクスビボ拡大のための組成物および方法

Country Status (5)

Country Link
US (2) US20170173083A1 (https=)
EP (2) EP3122181A4 (https=)
JP (3) JP2017511132A (https=)
CN (2) CN112063586A (https=)
WO (1) WO2015148716A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112063586A (zh) * 2014-03-26 2020-12-11 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
ES2966886T3 (es) 2014-05-09 2024-04-24 Univ Yale Partículas recubiertas con poliglicerol hiperramificado y métodos de elaboración y uso de las mismas
CA2986310A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
CN108026526B (zh) 2015-06-09 2023-05-12 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
US10669528B2 (en) 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
CN105238758A (zh) * 2015-09-17 2016-01-13 中国科学院广州生物医药与健康研究院 一种体外获得造血干/祖细胞的方法
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔ 標的化遺伝子編集を増強するための組成物およびその使用方法
EP4049665B1 (en) * 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2017205977A1 (en) * 2016-06-01 2017-12-07 Universite De Montreal Selection of human hematopoetic stem cells using epcr
CN106119204A (zh) * 2016-06-20 2016-11-16 何力丰 一种可用于干细胞和基因治疗的改造细胞的基因技术
SG11201901199WA (en) * 2016-08-18 2019-03-28 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
EP3541410B1 (en) * 2016-11-16 2024-03-27 Yeditepe Üniversitesi A combination inhibiting meis proteins
WO2018187493A1 (en) 2017-04-04 2018-10-11 Yale University Compositions and methods for in utero delivery
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
CN109207427B (zh) * 2018-09-17 2020-12-08 诺未科技（银川）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
CN109706119B (zh) * 2018-04-13 2020-11-27 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN110799641B (zh) * 2018-04-13 2021-02-19 诺未科技（北京）有限公司 丁酸钠的用途及含有丁酸钠的培养体系
IL260445B (en) * 2018-07-05 2019-08-29 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
US20210214699A1 (en) * 2018-07-05 2021-07-15 Lempo Therapeutics Ltd Methods and compositions for modulating myeloperoxidase (mpo) expression
CN109207426B (zh) * 2018-09-17 2020-08-21 诺未科技（北京）有限公司 一种将人造血祖细胞转变为造血干细胞的方法
CN109593714A (zh) * 2018-12-28 2019-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
WO2020057107A1 (zh) * 2018-09-17 2020-03-26 诺未科技（北京）有限公司 一种组合物及其用途
CN109593716B (zh) * 2018-12-28 2021-04-09 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109593715B (zh) * 2018-12-28 2020-12-08 北京承诺未来科技有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109536447A (zh) * 2018-12-28 2019-03-29 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
CN110592017B (zh) * 2019-07-12 2021-02-19 中国医学科学院血液病医院(中国医学科学院血液学研究所) 组蛋白甲基转移酶抑制剂在制备促进巨核细胞增殖或血小板产生的产品中的用途
MX2022007376A (es) 2019-12-20 2022-09-02 Tenaya Therapeutics Inc Fluoroalqull-oxadiazoles y sus usos.
IL307883A (en) 2021-04-23 2023-12-01 Tenaya Therapeutics Inc HDAC6 inhibitors for use in the treatment of dilated myocardial disease
US20240252502A1 (en) 2021-05-04 2024-08-01 Tenaya Therapeutics, Inc. Hdac6 inhibitors for treatment of metabolic disease and hfpef
CN114958744A (zh) * 2022-07-12 2022-08-30 上海派思维新生物医药科技有限公司 一种离体干细胞扩大培养方法和应用
WO2024154828A1 (ja) 2023-01-20 2024-07-25 国立大学法人熊本大学 培地、製造方法、及び細胞製剤
WO2025215092A1 (en) 2024-04-10 2025-10-16 Institut National de la Santé et de la Recherche Médicale Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE10002643A1 (de) * 2000-01-21 2001-07-26 Cognis Deutschland Gmbh Desodorierende Zubereitungen
WO2004046312A2 (en) * 2002-11-15 2004-06-03 The Board Of Trustees Of The University Of Illinois Methods for in vitro expansion of hematopoietic stem cells
CA2652888A1 (en) * 2006-05-26 2007-12-06 Celgene Corporation Methods and compositions using immunomodulatory compounds in combination therapy
NZ593447A (en) * 2008-12-03 2012-12-21 Harvard College Inhibition of hdac2 to promote memory
ES2769270T3 (es) * 2011-09-30 2020-06-25 Bluebird Bio Inc Compuestos para transducción viral mejorada
US20130136722A1 (en) * 2011-11-11 2013-05-30 The Board Of Trustees Of The University Of Illinois Methods of Ex Vivo Expansion of Blood Progenitor Cells, and Generation of Composite Grafts
US20150166969A1 (en) * 2012-02-24 2015-06-18 Fred Hutchinson Cancer Research Center Compositions and methods for the treatment of hemoglobinopathies
EP3196301B1 (en) * 2012-07-11 2018-10-17 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of monogenic diseases
SG10201701601WA (en) * 2012-08-29 2017-04-27 Sangamo Biosciences Inc Methods and compositions for treatment of a genetic condition
CN112063586A (zh) * 2014-03-26 2020-12-11 布里格姆及妇女医院股份有限公司 用于人造血干/祖细胞的离体扩增的组合物和方法

Similar Documents

Publication Publication Date Title
JP2020124212A5 (https=)
JP7844400B2 (ja) 異常ヘモグロビン症の治療用組成物および方法
AU2022200457A1 (en) Compositions and methods for the treatment of hemoglobinopathies
Jung et al. Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming
JP6525963B2 (ja) 血液疾患を治療するための、濃縮されかつ増殖したヒト臍帯血幹細胞
JP2019516754A5 (https=)
JP2024544746A5 (https=)
Xu et al. Therapeutic application of endothelial progenitor cells for treatment of cardiovascular diseases
JP2023526007A5 (https=)
JP7558814B2 (ja) 遺伝子治療
CN109475582A (zh) 基因递送的改进方法
JP2024541616A5 (https=)
JP2023548508A5 (https=)
Guo et al. Ex vivo expansion and homing of human cord blood hematopoietic stem cells
CN115087455A (zh) 用于治疗或预防克罗恩病的组合物和方法
Taebi et al. Genetic engineering in hematopoietic stem cells for β-Hemoglobinopathies treatment: advances, challenges, and clinical translation
JP2005514071A5 (https=)
US20250223562A1 (en) IMMUNOSELECTED UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS (UC-MSCs) AND DOWNSTREAM BIOLOGICS
Maalaoui Characterization of the UM171-Graft: Dissecting the lymphoid lineage potential of the UM171-Graft
Nasser et al. Rejuvenation and Regenerative Potential of Heart Stem Cells
HK40080440A (en) Compositions and methods for the treatment of hemoglobinopathies
RU2834231C2 (ru) Композиции и способы, предназначенные для лечения гемоглобинопатий
Mountford et al. Stem cell biology and the cardiovascular system
BR122025008935A2 (pt) Molécula de grna, método para alteração de uma célula-tronco hematopoiética (hsc) ou uma célula progenitora hematopoiética (hpc), composição, usos das mesmas, e método para preparação de uma célula- tronco hematopoiética (hsc) ou uma célula progenitora hematopoiética (hpc)
Shrestha Mechanism of Human Hematopoietic Stem Cell Loss During Ex Vivo Manipulation and Gene Transfer